On August 3, 2012, the United States Food and Drug Administration (USFDA) approved ziv-aflibercept injection ( Zaltrap, made by Sanofi and Regeneron Pharmaceuticals, Inc.) for use in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following treatment with an[…]
Aflibercept Approved for Colorectal Cancer Treatment
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approval News Tags: Afliberceptcolorectal cancerIrinotecan Aug 03, 2012
Is Capecitabine the Next Generic Blockbuster of Chemotherapy Drugs?
Bulk Active Ingredient, Chemotherapeutic / Anti-Neoplastic, Compounding API, Drug Research & Development API, Patent Expiration 2015 Tags: breast cancercolorectal cancer Jun 19, 2012
Regarded as a blockbuster drug used to treat both metastatic breast and colorectal cancer, Capecitabine is also known by the trade name Xeloda, which is marketed by Roche Pharamaceuticals. Capecitabine, CAS# 154361-50-9, is waiting in the wings to become a generic boon in the pharmaceutical industry, as the patent for Xeloda meets an expiration in[…]
Aflibercept Is Proving to be a Diverse and Effectual Product
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API Tags: AfliberceptAMDcolorectal cancer Mar 12, 2012
Clinical development of an exciting new recombinant fusion protein, Aflibercept, is underway. As an inhibitor of VEGF, or the vascular endothelial growth factor receptor, aflibercept is currently in a phase III trial for second line metastatic colorectal cancer. This trial for Aflibercept is being conducted by Sanofi-Aventis and Regeneron Pharmaceuticals. Additional trials currently in progress[…]
